Breast conservation is made more likely by neoadjuvant therapy in HER2-positive and triple-negative tumors, subtypes which showed the highest rates of clinically meaningful tumor reduction in the Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and molecular AnaLysis 1 (I-SPY 1) trial11. The gene discussed is ERBB2; the disease is neoplasm.